Clinical trial: Maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - A double-blind, placebo-controlled, randomized study

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 9, 2010, Pages 950-960

  Fass, R ^a   Delemos, B ^b   Nazareno, L ^c   Kao, R ^c   Xiang, J ^b   Lu, Y ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b Ortho McNeil Pharmaceutical Incorporated   (United States)

^c EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RABEPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIULCER AGENT;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; ESOPHAGUS INJURY; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARTBURN; HUMAN; LABORATORY TEST; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; SYMPTOM; VITAL SIGN; ADOLESCENT; AGED; DOSE RESPONSE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; ANTI-ULCER AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT; RABEPRAZOLE;

EID: 77950575679     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04254.x     Document Type: Article

References (23)

1. Fass R. Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003 98 : S2 7. (Pubitemid 36348508)
2. Bytzer P. Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients. Am J Gastroenterol 2003 98 : S31 9.
3. van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2006 3 : CD002095.
4. Fass R, Ofman JJ. Gastroesophageal reflux disease - should we adopt a new conceptual framework? Am J Gastroenterol 2002 97 : 1901 1909.
5. Bate CM, Griffin SM, Keeling PW, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996 10 : 547 555. (Pubitemid 26254798)
6. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997 32 : 974 979. (Pubitemid 27433659)
7. Kahrilas PJ, Miner P, Johanson J, Mao L, Jokubaitis L, Sloan S. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. Dig Dis Sci 2005 50 : 2009 2018. (Pubitemid 41504082)
8. Kahrilas PJ. Diagnosis of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003 98 : S15 23.
9. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998 10 : 119 124. (Pubitemid 28101879)
10. Hungin AP, Rubin G, O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999 49 : 463 464. (Pubitemid 29304147)
11. Zacny J, Zamakhshary M, Sketris I, Veldhuyzen van Zanten S. Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients. Aliment Pharmacol Ther 2005 21 : 1299 1312. (Pubitemid 40813676)
12. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999 13 : 907 914. (Pubitemid 29312776)
13. Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol Ther 2001 15 : 347 354. (Pubitemid 32187556)
14. Talley NJ, Venables TL, Green JR, et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002 14 : 857 863.
15. Scholten T, Dekkers CP, Schutze K, Korner T, Bohuschke M, Gatz G. On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trial. Digestion. 2005 72 : 76 85. (Pubitemid 41507266)
16. Kaspari S, Kupcinskas L, Heinze H, Berghofer P. Pantoprazole 20 mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2005 17 : 935 941. (Pubitemid 41192132)
17. Cooper A, Baxter G. Efficacy of lansoprazole on demand therapy in the treatment of non-erosive reflux disease and functional ulcer-like dyspepsia. Gut 2003 52 : A137.
18. Bytzer P, Blum A, De Herdt D, Dubois D. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2004 20 : 181 188. (Pubitemid 38998216)
19. Ponce J, Arguello L, Bastida G, Ponce M, Ortiz V, Garrigues V. On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. Dig Dis Sci 2004 49 : 931 936. (Pubitemid 39012275)
20. Bour B, Staub JL, Chousterman M, et al. Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment Pharmacol Ther 2005 21 : 805 812. (Pubitemid 40477240)
21. Bardhan KD, Muller-Lissner S, Bigard MA, et al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. BMJ 1999 318 : 502 507. (Pubitemid 29188994)
22. Hungin AP, Rubin GP, O'Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 1999 49 : 451 453. (Pubitemid 29304143)
23. Hughes DA, Bodger K, Bytzer P, De Herdt D, Dubois D. Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease. Pharmacoeconomics. 2005 23 : 1031 1041. (Pubitemid 41603436)